Company intelligence / Profile preview

CWind

Hangzhou, Zhejiang, China

Ownership: Private
Employees: ~150
Development stage: Other

Overview

Sciwind has shown robust clinical progress with ecnoglutide (long-acting GLP-1 analog) progressing to Phase 3/NDA for metabolic diseases, and multiple novel oral and antibody-based assets in early clinical development

Therapeutic areas: EndocrinologyCardiovascular
Modalities: PeptideAntibodySmall molecule
Industry: Biotech

Partnerships

Verdiva Bio (global licensing and collaboration, ex-Greater China and South Korea)

Beyond the preview

Go deeper on CWind.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CWind.

Explore the full profile